Edition:
India

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

1.65USD
23 Feb 2018
Change (% chg)

$-0.03 (-1.49%)
Prev Close
$1.67
Open
$1.65
Day's High
$1.65
Day's Low
$1.62
Volume
61,373
Avg. Vol
124,290
52-wk High
$24.00
52-wk Low
$1.60

Select another date:

Thu, Feb 8 2018

BRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc

* ADVENT LIFE SCIENCES LLP REPORTS A 4.5 PERCENT PASSIVE STAKE IN VERSARTIS, INC. AS OF DEC 31, 2017 - SEC FILING Source text - http://bit.ly/2EuDXO8 Further company coverage:

BRIEF-Versartis Inc Says Board Appointed Jay Shepard, CEO, To Position Of Principal Financial Officer

* VERSARTIS INC SAYS ‍ON NOV 28, 2017, BOARD APPOINTED JAY SHEPARD, CEO, TO POSITION OF PRINCIPAL FINANCIAL OFFICER, EFFECTIVE DEC 1, 2017 - SEC FILING​ Source text (http://bit.ly/2A3BTve) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Versartis hires Cowen to assist in evaluating potential strategic transactions

* Versartis hires Cowen to assist in evaluating potential strategic transactions

BRIEF-Versartis reports Q3 loss $1.40/shr

* Versartis reports third quarter 2017 financial results and provides corporate update

Versartis growth hormone drug fails key study, shares sink

Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

Versartis growth hormone drug fails key study, shares sink

Sept 21 Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

BRIEF-Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

* Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

Select another date: